Marker Therapeutics is a clinical-stage immuno-oncology company engaging in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines. Co. is developing three product candidates, including: autologous treatment of lymphoma, and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML); and off-the-shelf products in various indications. Co.'s clinical development programs are: MT-401, which is for the treatment of post-transplant AML; MT-401-OTS, which is for the treatment of AML; MT-601, which is for the treatment of pancreatic cancer; and MT-601, which is for the treatment of lymphoma. The MRKR YTD return is shown above.
The YTD Return on the MRKR YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether MRKR YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MRKR YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|